Acute effects of R -MDMA, S -MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants
Isabelle Straumann,Isidora Avedisian,Aaron Klaiber,Nimmy Varghese,Anne Eckert,Deborah Rudin,Dino Luethi,Matthias E. Liechti
DOI: https://doi.org/10.1038/s41386-024-01972-6
2024-08-25
Neuropsychopharmacology
Abstract:Racemic 3,4-methylenedioxymethamphetamine (MDMA) acutely increases mood, feelings of empathy, trust, and closeness to others and is investigated to assist psychotherapy. Preclinical research indicates that S -MDMA releases monoamines and oxytocin more potently than R -MDMA, whereas R -MDMA more potently stimulates serotonin 5-hydroxytryptamine-2A receptors. S -MDMA may have more stimulant properties, and R -MDMA may be more psychedelic-like. However, acute effects of S - and R -MDMA have not been examined in a controlled human study. We used a double-blind, randomized, placebo-controlled, crossover design to compare acute effects of MDMA (125 mg), S -MDMA (125 mg), R -MDMA (125 mg and 250 mg), and placebo in 24 healthy participants. Outcome measures included subjective, autonomic, and adverse effects, pharmacokinetics, and plasma oxytocin, prolactin, and cortisol concentrations. S -MDMA (125 mg) induced greater subjective effects ("stimulation," "drug high," "happy," "open") and higher increases in blood pressure than R -MDMA (both 125 and 250 mg) and MDMA (125 mg). Unexpectedly, R -MDMA did not produce more psychedelic-like effects than S -MDMA. S -MDMA increased plasma prolactin more than MDMA, and S -MDMA increased plasma cortisol and oxytocin more than MDMA and R -MDMA. The plasma elimination half-life of S -MDMA was 4.1 h after administration. The half-life of R -MDMA was 12 and 14 h after the administration of 125 and 250 mg, respectively. Half-lives for S -MDMA and R -MDMA were 5.1 h and 11 h, respectively, after racemic MDMA administration. Concentrations of the CYP2D6-formed MDMA-metabolite 4-hydroxy-3-methoxymethamphetamine were lower after R -MDMA administration compared with S -MDMA administration. The pharmacokinetic findings are consistent with the R -MDMA-mediated inhibition of CYP2D6. Stronger stimulant-like effects of S -MDMA in the present study may reflect the higher potency of S -MDMA rather than qualitative differences between S -MDMA and R -MDMA. Equivalent acute effects of S -MDMA, MDMA, and R -MDMA can be expected at doses of 100, 125, and 300 mg, respectively, and need to be investigated.
pharmacology & pharmacy,neurosciences,psychiatry